Abstract
611 Background: The use of adjuvant trastuzumab in women with HER2 positive early breast cancer also receiving adjuvant chemotherapy became standard of care in British Columbia in 2005. As the rand...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
